Holen Sie sich die Stockscreener-App
8.80
0.23%
0.02
Handel nachbörslich:
8.80
Schlusskurs vom Vortag:
$8.78
Offen:
$8.84
24-Stunden-Volumen:
78,054
Relative Volume:
0.97
Marktkapitalisierung:
$225.41M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.38M
KGV:
-6.2411
EPS:
-1.41
Netto-Cashflow:
$-15.54M
1W Leistung:
+4.64%
1M Leistung:
+7.32%
6M Leistung:
+29.03%
1J Leistung:
+28.28%
1-Tages-Spanne:
$8.51
$9.0253
1-Wochen-Bereich:
$8.12
$9.2156
52-Wochen-Spanne:
$5.55
$11.52
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Firmenname
Nuvectis Pharma Inc
Sektor
Branche
Telefon
360-837-7232
Adresse
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
8.80 | 224.90M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Maxim Group | Buy |
| 2025-03-17 | Eingeleitet | Laidlaw | Buy |
| 2022-07-13 | Eingeleitet | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Aktie (NVCT) Neueste Nachrichten
HC Wainwright Comments on Nuvectis Pharma Q1 Earnings - Defense World
HC Wainwright Predicts Nuvectis Pharma Q1 Earnings - MarketBeat
Nuvectis Pharma, Inc. reports 2025 financial results and business highlights - marketscreener.com
Nuvectis Pharma, Inc. SEC 10-K Report - TradingView
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights - The Manila Times
Risk Analysis: Does Nuvectis Pharma Inc. have a competitive edgeEarnings Miss & Precise Entry and Exit Recommendations - baoquankhu1.vn
Investment Report: Is Nuvectis Pharma Inc attractive for institutional investorsJuly 2025 WrapUp & Smart Swing Trading Techniques - baoquankhu1.vn
(NVCT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Nuvectis Pharma (NASDAQ:NVCT) Trading Up 5.8%Should You Buy? - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Trading Up 5.8% – Should You Buy? - Defense World
Is Nuvectis Pharma Inc. stock a buy on dipsQuarterly Growth Report & Real-Time Volume Spike Alerts - bollywoodhelpline.com
Will Nuvectis Pharma Inc. stock outperform value stocksInsider Selling & Precise Trade Entry Recommendations - bollywoodhelpline.com
Investment Report: Will Nuvectis Pharma Inc outperform tech stocksGold Moves & Safe Capital Growth Plans - baoquankhu1.vn
Energy Moves: Is Nuvectis Pharma Inc stock a good pick for beginnersRisk Management & Low Drawdown Trading Techniques - baoquankhu1.vn
Take Profit: Can Nuvectis Pharma Inc maintain its current growth rateBreakout Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Aug Spikes: Can Nuvectis Pharma Inc stock beat analyst upgradesJuly 2025 Recap & Real-Time Volume Spike Alerts - moha.gov.vn
What Wall Street predicts for Nuvectis Pharma Inc. stock price2025 Major Catalysts & Advanced Swing Trade Entry Plans - Улправда
We Think Nuvectis Pharma (NASDAQ:NVCT) Can Afford To Drive Business Growth - simplywall.st
Will Nuvectis Pharma Inc. stock benefit from commodity pricesSmall Cap Stock Opportunities & Grow Smarter With Pro-Level Research - Улправда
Why (NVCT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Laidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - MSN
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5%Here's Why - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5% – Here’s Why - Defense World
(NVCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Is Nuvectis Pharma Inc a good long term investmentEx-Dividend Date Alerts & High Return Trading Strategies - earlytimes.in
Why Nuvectis Pharma Inc. stock remains on buy listsFed Meeting & Growth Focused Stock Reports - Улправда
How rising interest rates impact Nuvectis Pharma Inc. stockEarnings Growth Summary & Verified Swing Trading Watchlists - DonanımHaber
Can Nuvectis Pharma Inc. stock beat analyst upgrades2025 Earnings Impact & Daily Growth Stock Investment Tips - DonanımHaber
Will Nuvectis Pharma Inc. stock keep outperforming rivalsMarket Sentiment Report & Entry and Exit Point Strategies - DonanımHaber
Will Nuvectis Pharma Inc. stock maintain dividend yield2025 Risk Factors & Weekly Stock Breakout Alerts - DonanımHaber
Weekly Recap: Will Nuvectis Pharma Inc. stock keep outperforming rivalsMarket Trend Summary & Capital Efficient Trade Techniques - bolumsonucanavari.com
Nuvectis Pharma announces initiation of Phase 1b study of NXP900 - MSN
Nuvectis Begins Phase 1b Study to Address Drug Resistance in Lung Cancer - socialunderground.co
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib By Investing.com - Investing.com Nigeria
Positive Recommendation on Nuvectis Pharma Driven by Promising Lead Candidate and Milestone Clinical Studies - TipRanks
Nuvectis Pharma Starts Phase 1b Study With Osimertinib for Non-Small Cell Lung Cancer - marketscreener.com
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib - Investing.com
Nuvectis Pharma announces the initiation of the phase 1b study of NXP900 in combination with osimertinib in patients with NSCLC - marketscreener.com
Nuvectis Pharma Initiates Phase 1b Study of NXP900 in Combination with Osimertinib for EGFRmut+ NSCLC Patients - Quiver Quantitative
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC - Sahm
Precision Trading with Nuvectis Pharma Inc. (NVCT) Risk Zones - Stock Traders Daily
Nuvectis Pharma Shares Gain Momentum on Analyst Backing and Clinical Progress - AD HOC NEWS
Nuvectis Pharma (NVCT) Stock Analysis Report | Financials & Insights - Benzinga
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insiders - Yahoo Finance
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; individual investors who hold 44% profited and so did insiders - simplywall.st
Technical Reactions to NVCT Trends in Macro Strategies - news.stocktradersdaily.com
Nuvectis Pharma (NASDAQ:NVCT) Trading 9.8% HigherHere's What Happened - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Trading 9.8% Higher – Here’s What Happened - Defense World
Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright - Investing.com Australia
Finanzdaten der Nuvectis Pharma Inc-Aktie (NVCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):